Added to YB: 2026-06-03
Pitch date: 2026-06-01
NAUT [bullish]
Nautilus Biotechnology, Inc.
-1.47%
current return
Author Info
Old Harbor Research shares independent equity research offering deep, differentiated, fundamental analysis on opportunities you likely haven’t heard about. Sign up for the newsletter.
Company Info
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
Market Cap
$352.0M
Pitch Price
$2.72
Price Target
4.50 (+64%)
Dividend
N/A
EV/EBITDA
-5.51
P/E
-6.13
EV/Sales
N/A
Sector
Life Sciences Tools and Services
Category
growth
Nautilus Biotechnology, Inc. - $NAUT
NAUT: Proteomics platform (Voyager) reads intact proteoforms/PTMs unlike mass spec & competitors (Olink, SomaScan, Quantum-Si). Nearing commercialization: EAP live, broadscale assay H1'27. Stock +243% LTM. $2B rev opportunity vs $348M cap, 100x potential. PT $4.50 (+64%). Risks: execution delays, mgmt overpromising, QSI competition.
Read full article (6 min)